封面
市场调查报告书
商品编码
1628896

皮肤癌诊断市场,按测试类型、癌症类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Skin Cancer Diagnostics Market, By Test Type, By Cancer Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023 年皮肤癌诊断市场规模为 91.145 亿美元,2024 年至 2032 年复合年增长率为 5.90%。

皮肤癌诊断市场-市场动态

皮肤癌发生率上升

近几十年来,皮肤癌一直是最常见的癌症类型之一,黑色素瘤和非黑色素瘤皮肤癌都变得越来越常见。据世界卫生组织 (WHO) 称,预计 2020 年将报告超过 150 万例新发皮肤癌病例。此外,欧盟委员会报告称,2020 年,皮肤黑色素瘤占欧盟 27 国所有新诊断癌症的 4%。它还导致 1.3% 的癌症死亡。皮肤癌是欧洲第六大最常被诊断出来的恶性肿瘤。随着包括皮肤癌在内的其他癌症的盛行率在全球范围内上升,预计全球皮肤癌诊断市场将在整个预测期内扩大。

皮肤癌诊断市场 - 关键见解

根据我们的研究分析师分享的分析,预计全球皮肤癌诊断市场在预测期内(2024-2032)每年将以 5.90% 左右的复合年增长率成长

根据测试类型细分,预计皮肤活检类别将在 2023 年显示最大的市场份额

根据癌症类型细分,2023 年非黑色素瘤是领先的细分市场

按地区划分,北美是 2023 年的主要收入来源

皮肤癌诊断市场-細項分析:

全球皮肤癌诊断市场根据测试类型、癌症类型、最终用户和地区进行细分。

根据测试类型,市场分为淋巴结活检、皮肤镜检查、影像测试、皮肤切片等。 2023年,皮肤活检细分市场占据了大部分市场份额。皮肤切片检查因其精确性、可靠性和适应性而成为皮肤癌诊断的黄金标准。它对于有效的皮肤癌筛检和治疗也至关重要。对皮肤活检的需求显着增加,预计未来几年将继续增加。由于可以在显微镜下检查令人担忧的皮肤病变,因此该过程也可以得出结论性的诊断。此外,它还有助于确定皮肤癌的类型及其属性,包括阶段和严重程度,以及病变是否是恶性的。

依最终用户划分,市场分为医院和诊所、实验室等。到 2023 年,医院和诊所将占据显着的市场份额,在皮肤癌诊断行业占据主导地位。在整个预测期内,该细分市场预计也将以最快的速度成长。皮肤癌盛行率的上升、诊断工具的改进以及早期诊断意识的增强都是促进皮肤癌诊断市场成长的因素。透过在医院整合人工智慧和远端皮肤病学,可以增加对医院皮肤癌诊断服务的需求,这可以进一步提高诊断的可及性和准确性。

皮肤癌诊断市场 - 地理洞察

从地理上看,皮肤癌诊断市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

2023年,北美地区皮肤癌诊断市占率最大。由于 Dermlite LLC、Castle Biosciences Inc. 和 Dermtech Inc. 等该地区领先公司在皮肤癌诊断产品的研发上投入了大量资金,北美皮肤癌诊断市场经历了显着扩张。此外,由于黑色素瘤发生率急剧上升,市场正在成长。此外,北美在皮肤癌诊断的发展方面处于领先地位,这为该地区的行业提供了巨大的潜在前景。

由于紫外线照射等环境变数不断增加、人们对皮肤癌的认识不断提高以及诊断技术的进步,预计亚太地区皮肤癌诊断市场将以最快的速度发展。随着政府计划鼓励皮肤癌的早期识别和治疗,医疗保健成本的上升和更容易获得医疗设施进一步推动了市场的扩张。此外,预计这些皮肤癌药物在亚太地区的监管批准,以及该地区发展中国家存在的规模庞大且不发达的市场,将支持亚太地区皮肤癌诊断市场的扩张。

皮肤癌诊断市场-竞争格局:

皮肤癌诊断市场的顶级公司包括 FOUNDATION MEDICINE, INC.、Castle Bioscience、DermTech、bioMerieux Inc.、DermaSensor, Inc. 等。重要的公司正在优先考虑维持高品质标准,并利用该地区当前的消费者基础来进入相当大的市场。在市场上建立信誉的品牌可以从这种策略中受益。这些公司正在尖端基础设施和技术方面进行大量投资,这使他们能够有效地处理和分析大量样本。为了增加市场占有率,企业也与经销商和其他企业进行许多策略活动。例如,诊断技术开发商SkylineDx于2024年1月获得欧洲专利号3827101,标誌着癌症诊断和客製化治疗的突破。该专利利用基因表现特征水平描述了对原发性皮肤黑色素瘤患者进行分类和治疗的新技术。

最新进展:

2024 年2 月:Quest Diagnostics 推出了MelaNodal Predict,这是一种非常复杂的预测性基因表现测试,旨在帮助黑色素瘤患者定制治疗选择,黑色素瘤是一种皮肤癌,也是美国最流行的疾病之一。

2024 年 1 月:DermaSensor Inc. 的非侵入性皮肤癌评估系统获得 FDA 批准,该系统采用人工智慧来识别常见的皮肤恶性肿瘤,如鳞状细胞癌、基底细胞癌和黑色素瘤。这款无线手持装置采用 FDA 批准的演算法,可提供快速、客观的资料,使医生能够评估可疑病变,而无需进行侵入性治疗。

2023 年 4 月:SkylineDx 和 NeraCare GmbH 宣布,他们将共同创建一项测试,使生命科学企业能够更快地推出关键的黑色素瘤治疗方法。

目录

第 1 章:皮肤癌诊断市场概述

  • 研究范围
  • 市场预估年份

第 2 章:执行摘要

  • 市场片段
    • 按测试类型分類的皮肤癌诊断市场片段
    • 按癌症类型分類的皮肤癌诊断市场片段
    • 最终用户的皮肤癌诊断市场片段
    • 按国家/地区分類的皮肤癌诊断市场片段
    • 按地区分類的皮肤癌诊断市场片段
  • 竞争洞察

第 3 章:皮肤癌诊断主要市场趋势

  • 皮肤癌诊断市场驱动因素
    • 市场驱动因素的影响分析
  • 皮肤癌诊断市场限制
    • 市场限制影响分析
  • 皮肤癌诊断市场机会
  • 皮肤癌诊断市场未来趋势

第 4 章:皮肤癌诊断产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章:皮肤癌诊断市场:COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章:皮肤癌诊断市场格局

  • 2023 年皮肤癌诊断市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章:皮肤癌诊断市场 - 按测试类型

  • 概述
    • 按测试类型分類的细分市场份额分析
    • 淋巴结活检
    • 皮肤镜检查
    • 影像学检查
    • 皮肤切片
    • 其他的

第 8 章:皮肤癌诊断市场 - 按癌症类型

  • 概述
    • 按癌症类型分類的细分市场份额分析
    • 黑色素瘤
    • 非黑色素瘤

第 9 章:皮肤癌诊断市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院和诊所
    • 实验室
    • 其他的

第 10 章:皮肤癌诊断市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美皮肤癌诊断主要製造商
    • 北美市场规模和预测(按国家)
    • 北美市场规模和预测(按测试类型)
    • 北美市场规模和预测(按癌症类型)
    • 北美市场规模和预测(按最终用户)
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲皮肤癌诊断主要製造商
    • 欧洲市场规模和预测(按国家)
    • 欧洲市场规模和预测(按测试类型)
    • 欧洲市场规模和预测(按癌症类型)
    • 欧洲市场规模和预测(按最终用户)
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区皮肤癌诊断主要製造商
    • 亚太地区市场规模与预测(按国家)
    • 按测试类型分類的亚太市场规模和预测
    • 亚太地区市场规模和预测(按癌症类型)
    • 亚太地区市场规模和预测(按最终用户)
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲皮肤癌诊断主要製造商
    • 拉丁美洲市场规模与预测(按国家)
    • 拉丁美洲市场规模和预测(按测试类型)
    • 拉丁美洲市场规模与预测(按癌症类型)
    • 拉丁美洲市场规模和预测(按最终用户)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲皮肤癌诊断主要製造商
    • 中东和非洲市场规模及预测(按国家)
    • 中东和非洲市场规模及预测(按测试类型)
    • 中东和非洲市场规模及预测(按癌症类型)
    • 中东和非洲市场规模和预测(按最终用户)
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章:主要供应商分析 - 皮肤癌诊断产业

  • 竞争仪表板
  • 公司简介
    • FOUNDATION MEDICINE, INC.
    • Castle Bioscience
    • DermTech
    • bioMerieux Inc.
    • DermaSensor, Inc.
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories
    • SkylineDx
    • Abbott
    • F Hoffmann-La Roche Ltd
    • Others

第 12 章:360 度分析师视角

第 13 章:附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4429

REPORT HIGHLIGHT

Skin Cancer Diagnostics Market size was valued at USD 9,114.5 Million in 2023, expanding at a CAGR of 5.90% from 2024 to 2032.

The procedure for identifying and diagnosing skin cancer is called skin cancer diagnostics. This encompasses a number of methods, including molecular pathology, histology, immunohistochemistry, electron microscopy, physical examination, and biopsy. Among the cancers that impact the skin is skin cancer. Skin cancer comes in three primary forms: squamous cell carcinoma, malignant melanoma, and basal cell carcinoma. Globally, the incidence of skin cancer is rising due to factors including ageing populations and prolonged UV exposure, which is driving the market for skin cancer diagnostics. This is driving the need for efficient diagnostic tools. Furthermore, more people are being encouraged to have regular tests for skin cancer due to rising public awareness and educational initiatives regarding the significance of early diagnosis.

Skin Cancer Diagnostics Market- Market Dynamics

Rising Incidence of Skin Cancer

Skin cancer has been one of the most common types of cancer in recent decades, with both melanoma and non-melanoma skin cancers becoming more common. Over 1.5 million new instances of skin cancer were anticipated to be reported in 2020, according to the World Health Organization (WHO). In addition, the European Commission reports that in 2020, cutaneous melanoma accounted for 4% of all new cancer diagnoses in the EU-27. It was also responsible for 1.3% of all deaths from cancer. Skin cancer is the sixth most often diagnosed malignancy in Europe. The global market for skin cancer diagnostics is expected to expand throughout the forecast period as the prevalence of other cancers, including skin cancer, rises worldwide.

Skin Cancer Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Skin Cancer Diagnostics Market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on test type segmentation, the skin biopsy category was predicted to show maximum market share in the year 2023

Based on cancer type segmentation, the non-melanoma was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Skin Cancer Diagnostics Market- Segmentation Analysis:

The Global Skin Cancer Diagnostics Market is segmented on the basis of Test Type, Cancer Type, End-user, and Region.

Based on test type, the market is segmented into Lymph Node Biopsy, Dermatoscopy, Imaging Tests, Skin Biopsy, and Others. The skin biopsy segment accounted for the majority of the market share in 2023. The most popular material for screening is skin biopsy, a medical technique in which a small sample of skin tissue is taken from the body. Skin biopsy is the gold standard for skin cancer diagnosis because of its precision, dependability, and adaptability. It is also essential for efficient skin cancer screening and treatment. The need for skin biopsies has increased significantly and is anticipated to continue to rise over the next several years. Because the worrisome skin lesion can be examined under a microscope, the process also yields a conclusive diagnosis. In addition, it assists in determining the type of skin cancer and its attributes, including stage and severity, as well as whether the lesion is malignant.

By end-user, the market is segmented into hospitals and clinics, laboratories, and others. With a significant market share in 2023, hospitals and clinics dominated the skin cancer diagnostics industry. Throughout the forecast period, this segment is also anticipated to increase at the fastest rate. The rising prevalence of skin cancer, improvements in diagnostic tools, and growing awareness of early diagnosis are all factors contributing to the skin cancer diagnostics market growth. The need for hospital-based skin cancer diagnostic services can be increased by integrating AI and teledermatology in hospitals, which can further improve diagnostic accessibility and accuracy.

Skin Cancer Diagnostics Market- Geographical Insights

Geographically, the Skin Cancer Diagnostics Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

In 2023, North America's share in the regional skin cancer diagnostics market was the greatest. Due to significant expenditures made in the research and development of skin cancer diagnostics products by leading companies operating in the region, including Dermlite LLC, Castle Biosciences Inc., and Dermtech Inc., the North American skin cancer diagnostics market has experienced significant expansion. Additionally, the market is growing due to the sharp rise in melanoma incidence. Furthermore, North America is leading the way in the development of skin cancer diagnostics, which offers significant potential prospects for the region's industry.

The market for skin cancer diagnostics is expected to develop at the quickest rate in the Asia Pacific due to rising environmental variables like UV exposure, growing awareness of skin cancer, and improvements in diagnostic technology. Along with government programs encouraging early identification and treatment of skin cancer, rising healthcare costs and easier access to medical facilities further fuel market expansion. Additionally, it is projected that the regulatory approvals for these skin cancer medications in the Asia Pacific, together with the existence of a sizable and underdeveloped market in the region's developing nations, will support the expansion of the skin cancer diagnostics market in Asia Pacific.

Skin Cancer Diagnostics Market- Competitive Landscape:

Among the top companies in the skin cancer diagnostics market are FOUNDATION MEDICINE, INC., Castle Bioscience, DermTech, bioMerieux Inc., DermaSensor, Inc., and others. Important firms are prioritizing upholding high standards of quality and gaining access to a sizable market by using the region's current consumer bases. Brands that have established credibility in the marketplace can benefit from this tactic. These companies are making significant investments in cutting-edge infrastructure and technology, which enables them to process and analyze a high volume of samples efficiently. In order to increase their market presence, businesses also engage in a number of strategic activities with distributors and other businesses. For instance, the diagnostics technology developer SkylineDx was granted European Patent No. 3827101 in January 2024, marking a breakthrough in cancer diagnosis and tailored therapy. Using gene expression signature levels, the patent describes new techniques for classifying and treating individuals with primary cutaneous melanoma.

Recent Developments:

February 2024: MelaNodal Predict, a very sophisticated predictive gene expression test, was introduced by Quest Diagnostics to assist in customizing treatment choices for patients with melanoma, a type of skin cancer and one of the most prevalent diseases in the United States.

January 2024: DermaSensor Inc. was granted FDA approval for its noninvasive skin cancer assessment system, which employs artificial intelligence to identify common skin malignancies like SCC, basal cell carcinoma, and melanoma. Using an FDA-approved algorithm, the wireless, handheld gadget gives quick, objective data, enabling doctors to assess suspected lesions without the need for intrusive treatments.

April 2023: SkylineDx and NeraCare GmbH announced that they will work together to create a test that would allow life science businesses to launch critical melanoma treatments more quickly.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SKIN CANCER DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • FOUNDATION MEDICINE, INC.
  • Castle Bioscience
  • DermTech
  • bioMerieux Inc.
  • DermaSensor, Inc.
  • Quest Diagnostics Incorporated.
  • NeoGenomics Laboratories
  • SkylineDx
  • Abbott
  • F Hoffmann-La Roche Ltd
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Lymph Node Biopsy
  • Dermatoscopy
  • Imaging Tests
  • Skin Biopsy
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Melanoma
  • Non-Melanoma

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals and Clinics
  • Laboratories
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Skin Cancer Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Skin Cancer Diagnostics Market Snippet by Test Type
    • 2.1.2. Skin Cancer Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Skin Cancer Diagnostics Market Snippet by End-user
    • 2.1.4. Skin Cancer Diagnostics Market Snippet by Country
    • 2.1.5. Skin Cancer Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Skin Cancer Diagnostics Key Market Trends

  • 3.1. Skin Cancer Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Skin Cancer Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Skin Cancer Diagnostics Market Opportunities
  • 3.4. Skin Cancer Diagnostics Market Future Trends

4. Skin Cancer Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Skin Cancer Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Skin Cancer Diagnostics Market Landscape

  • 6.1. Skin Cancer Diagnostics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Skin Cancer Diagnostics Market - By Test Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Test Type, 2023 & 2032 (%)
    • 7.1.2. Lymph Node Biopsy
    • 7.1.3. Dermatoscopy
    • 7.1.4. Imaging Tests
    • 7.1.5. Skin Biopsy
    • 7.1.6. Others

8. Skin Cancer Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 8.1.2. Melanoma
    • 8.1.3. Non-Melanoma

9. Skin Cancer Diagnostics Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals and Clinics
    • 9.1.3. Laboratories
    • 9.1.4. Others

10. Skin Cancer Diagnostics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Skin Cancer Diagnostics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Skin Cancer Diagnostics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Skin Cancer Diagnostics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Skin Cancer Diagnostics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Skin Cancer Diagnostics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Skin Cancer Diagnostics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. FOUNDATION MEDICINE, INC.
    • 11.2.2. Castle Bioscience
    • 11.2.3. DermTech
    • 11.2.4. bioMerieux Inc.
    • 11.2.5. DermaSensor, Inc.
    • 11.2.6. Quest Diagnostics Incorporated.
    • 11.2.7. NeoGenomics Laboratories
    • 11.2.8. SkylineDx
    • 11.2.9. Abbott
    • 11.2.10. F Hoffmann-La Roche Ltd
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us